LRRC32 and melanoma: IFN-α is one of the classical immunotherapeutic strategies used in the treatment of melanoma in an adjuvant setting.[27, 28] It has been described to exert beneficial immunomodulatory effects in Treg and melanoma cells.[29] Therefore, we analyzed the impact of IFN-α on GARP expression of melanoma and Treg.